A Phase 2 Umbrella Protocol of Enfortumab Vedotin As Monotherapy and Combined with Other Agents in Patients with Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Enfortumab vedotin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ENCORE
- 03 Jul 2024 Planned End Date changed from 1 Sep 2026 to 1 Sep 2027.
- 03 Jul 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2025.
- 27 Jan 2024 Results of 11 patients in stage I presented at the 2024 Genitourinary Cancers Symposium.